natgillin/translations-raw huggingface dataset:
Patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) have not been studied (see section 5.3).
Uporaba pri bolnikih s hudo okvaro ledvic (opredeljeno kot eGFR < 30 ml/min/1,73 m2) ni raziskana (glejte poglavje 5.3).
Patients with severe renal impairment (eGFR <30 ml/min per 1.73 m2).
Bolniki s hudo okvaro ledvic (eGFR < 30 ml/min na 1,73 m2).
Patients with severe renal impairment receiving Eperzan experienced a higher frequency of diarrhoea, nausea, and vomiting compared to patients with mild or moderate renal impairment.
Bolniki s hudo okvaro ledvic, ki so prejemali zdravilo Eperzan, so imeli drisko, navzeo in bruhanje pogosteje kot bolniki z blago ali zmerno okvaro ledvic.
Patients with severe renal impairment should not receive GRANUPAS.
Bolniki s hudo okvaro ledvic ne smejo uporabljati zdravila GRANUPAS.
Patients with severe renal impairment showed no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (Cmax and AUC) following administration of umeclidinium/vilanterol with umeclidinium at twice the recommended dose and vilanterol at the recommended dose and no evidence of altered protein binding between patients with severe renal impairment and healthy volunteers.
Pri bolnikih s hudo okvaro ledvic po uporabi kombinacije umeklidinij/vilanterol (umeklidinij v dvakratnem priporočenem odmerku in vilanterol v priporočenem odmerku) niso ugotovili večje sistemske izpostavljenosti umeklidiniju ali vilanterolu (Cmax in AUC); prav tako pri bolnikih s hudo okvaro ledvic v primerjavi z zdravimi prostovoljci niso odkrili znakov spremenjene vezave na beljakovine.
Patients with severe renal impairment whose weight falls outside the 62 to 114 kg range (see section 5.2) need to reduce their mg/kg dose by 50 %.
Bolniki s težkimi ledvičnimi okvarami, katerih telesna teža je zunaj meja 62 do 114 kg (glejte poglavje 5.2), morajo prejemati 50 % manjši odmerek v mg/kg.
Patients with severe renal impairment, i.e. creatinine clearance (CrCl) <30 ml/min, including patients undergoing haemodialysis (see section 4.4).
Bolniki s hudo ledvično okvaro, npr. z očistkom kreatinina (CrCl) <30 ml/min, vključno z bolniki na hemodializi (glejte poglavje 4.4).
Patients with severe renal impairment.
Bolnice s hudo ledvično okvaro.
Patients with severe rheumatoid arthritis and other inflammatory diseases, who have had the disease for a long time, may be at higher than average risk of developing lymphoma.
Bolniki s hudim revmatoidnim artritisom in drugimi vnetnimi boleznimi, ki imajo to bolezen dolgo časa, imajo lahko tudi več kot povprečno tveganje za nastanek limfoma.
Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher than average risk of developing lymphoma.
Bolniki s hudo obliko revmatoidnega artritisa, ki imajo to bolezen že dolgo časa, imajo lahko večje tveganje od povprečja za nastanek limfoma.
Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher than average risk of developing lymphoma.
Bolniki z resnejšo obliko revmatoidnega artritisa, ki imajo to bolezen že dolgo časa, imajo lahko večje tveganje od povprečja za nastanek limfoma.
Patients with severe, debilitating medical conditions
Bolniki s hudimi boleznimi, ki bolnika onesposobijo;
Patients with severe, debilitating medical conditions.
Bolniki s hudimi boleznimi, ki bolnika onesposobijo;
Patients with severe, debilitating medical conditions.
hude bolezni, ki bolnika onesposobijo;
Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day.
Bolniki s hudi okvaro delovanja ledvic morajo prejemati nižji začetni 20-miligramski odmerek enkrat na dan.
Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day.
Bolniki s hudo okvaro delovanja ledvic morajo prejemati nižji začetni 20-miligramski odmerek enkrat na dan.
Patients with sickle cell anaemia
Bolniki s srpastocelično anemijo
Patients with significant cardiac dysfunction (congestive heart failure [NY Heart Association Class III or IV]; myocardial infarction within 12 months of starting study; unstable or poorly controlled angina pectoris) were excluded from clinical studies with pomalidomide.
Bolniki s pomembno srčno disfunkcijo (kongestivno srčno popuščanje [razred III ali IV po razvrstitvi NYHA]; miokardni infarkt v 12 mesecih od začetka študije; nestabilna ali slabo nadzirana angina pektoris) so bili iz kliničnih študij s pomalidomidom izključeni.
Patients with significant left ventricular dysfunction
bolniki z znatno oslabelim delovanjem levega ventrikla,
Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1).
Bolnike s pomembnimi dejavniki tveganja za srčnožilne dogodke (npr. hipertenzija, hiperlipidemija, diabetes mellitus, kajenje) lahko s celekoksibom zdravimo le po skrbnem premisleku (glejte poglavje 5.1).
Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with parecoxib after careful consideration (see section 5.1).
Bolnike s pomembnimi dejavniki tveganja za srčnožilne dogodke (npr. hipertenzija, hiperlipidemija, diabetes mellitus, kajenje) lahko zdravimo s parekoksibom le po skrbnem premisleku (glejte poglavje 5.1).
Patients with significantly compromised cardiac function, e.g., NYHA Class III/IV.
Bolniki z izrazito kompromitirano srčno funkcijo, na primer stopnja III/IV po NYHA klasifikaciji.
Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid arthritis.
Bolniki z občutno okvarjenim delovanjem kostnega mozga ali izrazito anemijo, levkopenijo, nevtropenijo ali trombocitopenijo, katerih vzrok ni revmatoidni artritis.
Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid or psoriatic arthritis,
Bolniki z občutno okvarjenim delovanjem kostnega mozga ali izrazito anemijo, levkopenijo, nevtropenijo ali trombocitopenijo, katerih vzrok ni revmatoidni ali psoriatični artritis.
Patients with significantly impaired bone marrow function or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid or psoriatic arthritis.
Bolniki z občutno okvarjenim delovanjem kostnega mozga ali izrazito anemijo, levkopenijo, nevtropenijo ali trombocitopenijo, katerih vzrok ni revmatoidni ali psoriatični artritis.
Patients with significantly impaired bone marrowfunction or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid or psoriatic arthritis.
Bolniki z občutno okvarjenim delovanjem kostnega mozga ali izrazito anemijo, levkopenijo, nevtropenijo ali trombocitopenijo, katerih vzrok ni revmatoidni artritis ali psoriatični artritis.
Patients with significantly impaired bone marrowfunction or significant anaemia, leucopenia, neutropenia or thrombocytopenia due to causes other than rheumatoid or psoriaticarthritis.
Bolniki z občutno okvarjenim delovanjem kostnega mozga ali izrazito anemijo, levkopenijo, nevtropenijo ali trombocitopenijo, katerih vzrok ni revmatoidni artritis ali psoriatični artritis.
Patients with signs or symptoms of muscle toxicity should be managed as per standard medical practice.
Bolnike z znaki ali simptomi toksičnih učinkov na mišice je treba obravnavati v skladu s standardno zdravniško prakso.
Patients with signs or symptoms of NYHA Class III or IV cardiac failure, recent history of myocardial infarction (in the last 4 months), and in patients with uncontrolled angina or arrhythmias, should have a comprehensive medical assessment, prior to starting treatment with Kyprolis.
Bolnike z znaki ali simptomi srčnega popuščanja v razredih III. ali IV. po NYHA, anamnezo nedavnega miokardnega infarkta (v zadnjih 4 mesecih) in bolnike z neobvladano angino pektoris ali motnjami srčnega ritma je treba pred začetkom zdravljenja z zdravilom Kyprolis celovito zdravstveno oceniti.
Patients with single organ dysfunction and recent surgery
Bolniki z okvarjenim delovanjem enega organa in nedavnim operacijskim posegom
Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
Bolniki s skeletnimi malignostmi ali kostnimi metastazami morajo biti izključeni iz zdravljenja s teriparatidom
Patients with SMEI would not be expected to drive or operate machinery due to the nature of the underlying disease and the effects of long term administration of anticonvulsant medicines.
Za bolnike s SMEI se zaradi narave obstoječe bolezni in učinkov dolgoročnega dajanja antikonvulzivnih zdravil vožnja oz. upravljanje s stroji ne pričakuje.
Patients with specific forms of psoriasis like guttate, erythrodermic or pustular psoriasis as sole or predominant form of psoriasis.
Bolniki s specifičnimi oblikami psoriaze kot so gutatna, eritrodermična ali pustulozna psoriaza bodisi sama ali kot predominantna oblika psoriaze.
Patients with squamous histology are at higher risk of developing serious pulmonary bleeding, however, no excess of Grade 5 pulmonary haemorrhage was observed in ramucirumab treated patients with squamous histology in REVEL.
Pri bolnikih s ploščatocelično histologijo obstaja večje tveganje za razvoj resnih pljučnih krvavitev, vendar pa v študiji REVEL pri bolnikih, zdravljenih z ramucirumabom, ki so imeli ploščatocelično histologijo, niso opazili pljučnih krvavitev, ki bi presegale stopnjo 5.
Patients with Still’s disease may develop a condition called macrophage activation syndrome (MAS), which can be life-threatening.
Pri bolnikih s Stillovo boleznijo lahko pride do motnje, ki jo imenujemo sindrom aktivacije makrofagov in je lahko življenjsko nevarna.
Patients with suboptimal response to inhaled nitric oxide (iNO) despite at least 4 hours of continuous treatment were treated with bosentan dispersible tablets at 2 mg/kg twice daily (N = 13) or placebo (N = 8) via nasogastric tube as add-on therapy on top of iNO until complete weaning of iNO or until treatment failure (defined as need for extra-corporeal membrane oxygenation [ECMO] or initiation of alternative pulmonary vasodilator) and for a maximum of 14 days.
Bolniki s suboptimalnim odzivom na vdihavanje duškovega oksida (iNO) kljub vsaj 4 ure trajajoči neprekinjeni terapiji so prejemali disperzibilne tablete bosentana 2 mg/kg dvakrat dnevno (N = 13) ali placebo (N = 8) po nazogastrični sondi kot dodatno terapijo poleg iNO do popolne ukinitve iNO ali do neuspeha zdravljenja (opredeljen kot potreba po izventelesni membranski oksigenaciji [ECMO] ali uvedba alternativnega pljučnega vazodilatatorja) in to največ 14 dni.
Patients with suicidal ideation and/or behaviour* [n (%)]**
bolniki s samomorilnimi mislimi in/ali vedenjem* [n (%)]
Patients with symptomatic ovarian cysts should be referred for further evaluation.
Bolnice s simptomatskimi ovarijskimi cistami je treba nadaljno oceniti.
Patients with symptoms of cerebral oedema, such as morning headaches with vomiting, or changes in vision, should speak to their doctor, as treatment with Cystadane may have to be interrupted.
Bolniki s simptomi možganskega edema, kot so jutranji glavobol z bruhanjem, ali spremembami vida, naj se posvetujejo s svojim zdravnikom, saj utegne biti potrebno prekiniti zdravljenje z zdravilom Cystadane.
Patients with symptoms of heart failure at rest or with minimal exertion within the previous month prior, or who were hospitalised for heart failure during the previous month.
Bolniki s simptomi srčnega popuščanja v mirovanju ali med minimalnim naporom v preteklem mesecu predhodno, ali ki so bili hospitalizirani zaradi srčnega popuščanja v preteklem mesecu
Patients with terminal renal insufficiency should be closely monitored, since it is expected that the level of circulating oestrogens components of DUAVIVE will be increased.
Pričakovati je, da bo raven estrogenskih komponent zdravila DUAVIVE v obtoku zvišana, zato je treba bolnice s končnim stadijem ledvične insuficience pozorno spremljati.
Patients with thalassaemia major need frequent blood transfusions.
Bolniki z veliko talasemijo potrebujejo pogosto transfuzijo krvi.
Patients with the complete deletion/large rearrangement genotype
Bolniki z genotipom s popolno delecijo/obsežno preureditvijo
Patients with the disease produce too much IL-6 and this is thought to contribute to the abnormal growth of certain cells in the lymph nodes.
Pri bolnikih s Castlemanovo boleznijo se tvori preveč interlevkina-6, kar domnevno prispeva k nenormalni rasti določenih celic v bezgavkah.
Patients with the following conditions were excluded from clinical trials: active CNS metastases; HIV, hepatitis B or hepatitis C infection; active systemic autoimmune disease; interstitial lung disease; prior pneumonitis requiring systemic corticosteroid therapy; a history of severe hypersensitivity to another monoclonal antibody; receiving immunosuppressive therapy and a history of severe immune-related adverse reactions from treatment with ipilimumab, defined as any Grade 4 toxicity or Grade 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent) for greater than 12 weeks.
V klinična preskušanja niso bili vključeni bolniki z: aktivnimi metastazami v osrednjem živčevju, okužbo s HIV, hepatitisom B ali hepatitisom C, aktivno sistemsko avtoimunsko boleznijo, intersticijsko boleznijo pljuč, predhodnim pnevmonitisom, ki je zahteval sistemsko zdravljenje s kortikosteroidi, anamnezo hude preobčutljivosti za drugo monoklonsko protitelo, ki se zdravijo z imunosupresivi in z anamnezo hudih imunsko pogojenih neželenih učinkov med zdravljenjem z ipilimumabom, opredeljenih kot toksičnost 4. ali 3. stopnje, ki je zahtevala več kot 12 tedensko zdravljenje s kortikosteroidi (> 10 mg/dan prednizona ali ekvivalenta).
Patients with the highest tumour burden as measured by the percentage of bone marrow blast cells at baseline (≥ 90%) still had a clinically meaningful response with a CR/CRh* rate of 21.6% (CI 12.9 – 32.7) (see figure 1).
Tudi bolniki z največjim tumorskim bremenom, merjenim kot izhodiščni odstotek blastnih celic v kostnem mozgu (≥ 90 %), so dosegli klinično pomemben odziv z deležem CR/CRh* 21,6 % (IZ 12,9-32,7) (glejte sliko 1).
Patients with the T790M mutation currently have a poor prognosis and very limited treatment options; therefore there is a high unmet medical need.
Bolniki z mutacijo T790M imajo trenutno slabo prognozo in zelo omejene možnosti zdravljenja, zato obstaja velika neizpolnjena medicinska potreba.
Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation (see section 4.4).
Bolnike s temi lastnostmi je potrebno skrbno spremljati glede znakov in simptomov jetrne dekompenazcije.
patients with thyroid disease unless it is controlled,
bolnikih z boleznijo ščitnice, razen če je obvladana,
Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with zoledronic acid outweighs the possible risk.
Bolnike s tumorsko povzročeno hiperkalciemijo (TIH) in z znaki poslabšanja ledvične funkcije, moramo ustrezno ovrednotiti in pri tem pretehtati, ali možna korist zdravljenja z zoledronsko kislino odtehta možna tveganja.
Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with Zoledronic acid Teva outweighs the possible risk.
Bolnike s tumorsko povzročeno hiperkalciemijo (TIH) in z znaki poslabšanja ledvične funkcije, moramo ustrezno ovrednotiti in pri tem pretehtati, ali možna korist zdravljenja z zdravilom Zoledronska kislina Teva odtehta možno nevarnost.
Patients with TIH with evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with zoledronic acid outweighs the possible risk.
Bolnike s tumorsko povzročeno hiperkalciemijo (TIH) z znaki poslabšanja ledvične funkcije, moramo ustrezno ovrednotiti in pri tem pretehtati, ali možna korist zdravljenja z zoledronsko kislino odtehta možno tveganje.
Patients with transaminase elevations should be managed by withholding bosutinib temporarily (with consideration given to dose reduction after recovery to grade 1 or baseline), and/or discontinuation of bosutinib.
Pri bolnikih s povečanimi vrednostmi transaminaz je treba začasno prekiniti zdravljenje z bosutinibom (pri tem je treba upoštevati zmanjšanje odmerka po izboljšanju na stopnjo 1 ali na izhodiščno vrednost) in/ali dokončno prekiniti zdravljenje z bosutinibom.
Patients with treated brain metastases were eligible for enrollment if they did not require therapy to control symptoms.
Bolniki z metastazami na možganih so bili primerni za vključitev, če za obvladovanje simptomov niso potrebovali zdravljenja.
Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2 weeks prior to enrolment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents.
Bolniki z zdravljenimi zasevki v možganih so bili primerni za vključitev, če se je nevrološko stanje povrnilo do izhodiščnega stanja vsaj 2 tedna pred vključitvijo in se niso zdravili s kortikosteroidi ali pa so se zdravili s stabilnim ali manjšajočim se odmerkom kortikosteroida, ki je ustrezal < 10 mg prednizona na dan.
Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2 weeks prior to enrolment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents.
Bolniki z zdravljenimi zasevki v možganih so bili primerni za vključitev, če se je nevrološko stanje povrnilo do izhodiščnega stanja vsaj 2 tedna pred vključitvijo in se niso zdravili s kortikosteroidi ali pa so se zdravili s stabilnim odmerkom ali z nižanjem odmerka kortikosteroida, ki je ustrezal < 10 mg prednizona na dan.
Patients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections (see section 4.4).
Bolniki s tuberkulozo ali z drugimi hudimi okužbami, kakor so npr. sepsa, abscesi in oportunistične okužbe (glejte poglavje 4.4).
Patients with tumour PD-L1 expression by all predefined expression levels in the OPDIVO group demonstrated greater likelihood of improved survival compared to docetaxel, whereas survival was similar to docetaxel in patients with low or no tumour PD-L1 expression.
Pri bolnikih z ekspresijo PD-L1 tumorja v skupini z zdravilom OPDIVO so pri vseh vnaprej določenih vrednostih ekspresije ugotovili večjo verjetnost izboljšanja preživetja v primerjavi z bolniki v skupini z docetakselom, kjer je bilo preživetje podobno kot pri uporabi docetaksela pri bolnikih z majhno ekspresijo PD-L1 tumorja ali brez nje.
Patients with tumours can have high levels of calcium in their blood, released from the bones.
Bolniki s tumorji imajo lahko v krvi visoke ravni kalcija, ki se sprošča iz kosti.
patients with tumours of the adrenal glands (small glands located on top of the kidneys) such as pheochromocytoma and paraganglioma;
bolnikih s tumorjem nadledvičnih žlez (majhnih žlez na vrhu ledvic), kot sta feokromocitom in paragangliom;
Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temomedac only
Bolniki s tumorji, ki so se pojavili znova ali so se poslabšali (maligni gliomi, kot sta multiformni glioblastom ali anaplastični astrocitom) in jemljejo samo zdravilo Temomedac
Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temozolomide Hexal only:
Bolniki s tumorji, ki so se ponovili ali poslabšali (maligni gliomi, kot sta multiformni glioblastom ali anaplastični astrocitom) in jemljejo samo zdravilo Temozolomid Hexal
Patients with two Events
bolniki z dvema dogodkoma
Patients with two Events
kupni dogodki
Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.
Bolniki z diabetesom tipa 1 morajo še naprej uživati vsaj malo ogljikovih hidratov, čeprav zmorejo užiti le malo ali nič hrane ali če bruhajo itn., ter ne smejo nikoli povsem opustiti insulina.
Patients with type 2 diabetes treated with naltrexone / bupropion demonstrated a higher incidence of gastrointestinal adverse events, primarily nausea, vomiting, and diarrhoea, than subjects without diabetes.
Pri bolnikih s sladkorno boleznijo tipa 2, zdravljenih z naltreksonom/bupropionom, je bila pojavnost neželenih učinkov na prebavila, primarno navzee, bruhanja in driske, večja kot pri preiskovancih brez sladkorne bolezni.
Patients with uncontrolled hypertension (see section 4.4)
Bolniki z nenadzorovano hipertenzijo (glejte poglavje 4.4)
Patients with uncontrolled hypertension were excluded from the trials: ramucirumab treatment should not be initiated in such patients until and unless their pre-existing hypertension is controlled.
Bolniki z neuravnano hipertenzijo so bili izvzeti iz preskušanj: zdravljenja z ramucirumabom pri takih bolnikih ne smete uvesti, dokler oziroma v kolikor obstoječa hipertenzija ni uravnana.
Patients with uncontrolled or significant cardiovascular disease including QT interval prolongation, at baseline, were not included in clinical studies (see sections 5.1 and 5.3).
Bolniki, ki so imeli na začetku študije nenadzorovane ali hude bolezni srca, vključno s podaljšanjem intervala QT, niso bili vključeni v klinične študije (glejte poglavji 5.1 in 5.3).
Patients with underlying cancer who are at heightened risk of GI perforation, such as those with:
Bolniki z osnovno onkološko boleznijo, ki imajo večje tveganje za perforacijo prebavil, npr. osebe
Patients with underlying renal disease may experience exacerbation or decompensation of their renal disease while on NSAID therapy. (See also section 4.6).
Pri živalih s prikrito boleznijo ledvic lahko med zdravljenjem z nesteroidnimi protivnetnimi zdravili pride do poslabšanja ali dekompenzacije ledvične bolezni (glejte tudi poglavje 4.6)
patients with underlying systemic or
bolnikih s sistemsko ali ledvično boleznijo, ali pri bolnikih, ki
Patients with undetectable HCV-RNA at treatment week 12 and SVR upon retreatment
Bolniki, pri katerih je bila vrednost HCV–RNA nemerljiva v 12. tednu zdravljenja in SVR pri ponovnem zdravljenju
Patients with undetectable HCV–RNA
(≤600.000 i.e./ml)
Patients with undetectable HCV–RNA
49,5 (95/192)
Patients with undetectable hepatitis C virus ribonucleic acid (HCV RNA) (target not detected) at weeks 4 and 12 receive an additional 12 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 24 weeks.
Bolniki z nezaznavno koncentracijo ribonukleinske kisline virusa hepatitisa C (HCV RNK) (nezaznaven analit) v 4. in 12. tednu naj prejemajo samo peginterferon alfa in ribavirin še dodatnih 12 tednov, do skupnega trajanja zdravljenja 24 tednov.
patients with unstable angina or angina occurring during sexual intercourse, patients with New York Heart Association Class 2 or greater heart failure in the last 6 months, patients with uncontrolled arrhythmias, hypotension (< 90/50 mm Hg), or uncontrolled hypertension, patients with a stroke within the last 6 months.
bolniki z nestabilno angino pektoris ali angino pektoris, ki se pojavlja med spolnim odnosom, bolniki s srčnim odpovedovanjem razreda 2 ali višjim po NYHA (New York Heart Association) v zadnjih 6 mesecih, bolniki z nekontroliranimi aritmijami, hipotenzijo (< 90/50 mm Hg) ali nekontrolirano hipertenzijo, bolniki, ki so v zadnjih 6 mesecih doživeli možgansko kap.